Sign in

    Natalya Davies

    Research Analyst at Intron Health Research

    Natalya Davies is an Equity Analyst specializing in healthcare at Intron Health, where she joined in July 2024. Her coverage includes key publicly listed biotech and pharmaceutical companies, having participated in major earnings calls such as Vivoryon Therapeutics, where her insights have been cited by management. Although recent to Intron Health, her early tenure is marked by detailed industry analysis and engagement with senior sector management. Davies holds advanced professional credentials relevant to financial analysis and healthcare markets, though specific securities licenses and historical firm affiliations are not yet publicly detailed.

    Natalya Davies's questions to IRONWOOD PHARMACEUTICALS (IRWD) leadership

    Natalya Davies's questions to IRONWOOD PHARMACEUTICALS (IRWD) leadership • Q3 2024

    Question

    Natalya Davies inquired about expectations for a potential increase in SG&A expenses related to prelaunch costs for apraglutide and the outlook for R&D spending in 2025.

    Answer

    Sravan Emany, COO and CFO, stated that specific 2025 guidance would be provided next year. However, he emphasized that the company plans to leverage its significant existing commercial infrastructure for the apraglutide launch, implying potential cost efficiencies rather than a major jump in spending.

    Ask Fintool Equity Research AI